Cheaper HIV Prevention Injection Could Benefit Zimbabwe
The US Food and Drug Administration has given tentative approval to a generic version of lenacapavir, a twice-yearly injection that prevents HIV infection.
The US Food and Drug Administration has given tentative approval to a generic version of lenacapavir, a twice-yearly injection that prevents HIV infection. The generic comes from India’s Dr Reddy’s Laboratories and could reach up to 120 low- and middle-income countries at about US$40 per person per year. This marks a sharp drop from the branded version’s US list price of US$28,218 a year.
If Zimbabwe adds the injection to its national HIV prevention programme, the lower cost could ease pressure on public health budgets that currently fund treatment for new infections. Fewer cases would also protect household incomes by keeping more people in the workforce and cutting long-term hospital bills.
Lenacapavir is given as two injections a year instead of daily pills. Two large clinical studies showed it almost eliminated new HIV infections in people at high risk. The generic was developed through a deal involving Unitaid, the Clinton Health Access Initiative and South Africa’s Wits RHI. Gilead Sciences, the original maker, has granted royalty-free licences to six manufacturers for use in Africa, Asia and Latin America.
Demand for the drug has already outstripped supply when only the branded product was available. The generic must be used only after HIV testing to avoid creating drug resistance. Patients need further tests before each injection. Reported side effects include reactions at the injection site, headaches and nausea.
Zimbabwe still needs to complete regulatory approval, arrange procurement and secure financing before the injection can be rolled out. The licensing deal alone does not set a launch date. Health groups say governments and donors must find money to buy the medicine and train staff to reach at-risk communities.
The economic case is clear. Each prevented infection saves the country the cost of lifelong treatment and lost productivity. For a nurse abroad sending money home, or a family business owner in Harare, that means less strain on stretched household and national resources in the years ahead.
The next step to watch is whether Zimbabwe’s health ministry secures funding and finalises supply deals in the coming months.
- High Court Throws Out SA Company's Challenge Over Zimra's U.S.$80,000 Truck Seizure
- Why Couldn’t Zimbabwe Play at Home for Five Years?
- Zimbabwe Stock Market Falls as VFEX Drops 3.60% and ZSE Loses 0.60%
- Zimbabwean billionaire Strive Masiyiwa's Cassava to offer quantum-safe networks in Africa from 2027
- Africa: Zimbabwe Slips Four Places to 14th Out of 29 in Africa's Digital Rights and Inclusion Ranking
- Zimbabwe’s ZiG Yield Curve Plan Tests Confidence in Local Currency Savings
- Haruzivishe blames ZANU PF and opposition for Zimbabweans dying in Ukraine
- South African tycoons Mark and Brett Levy to build $21.8 million solar plant